Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VLON - Vallon Pharmaceuticals Inc


Previous close
360
0   0%

Share volume: 1,237
Last Updated: Fri 21 Apr 2023 06:00:00 AM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$360.00
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
10.50%
1 Month
-2.44%
3 Months
39.13%
6 Months
24.22%
1 Year
-82.38%
2 Year
-91.09%
Key data
Stock price
$360.00
P/E Ratio 
0.00
DAY RANGE
N/A - $360.00
EPS 
$0.00
52 WEEK RANGE
$184.86 - $1,953.00
52 WEEK CHANGE
-$0.82
MARKET CAP 
9.707 B
YIELD 
N/A
SHARES OUTSTANDING 
13.482 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,640
AVERAGE 30 VOLUME 
$869
Company detail
CEO:
Region: US
Website: www.vallon-pharma.com
Employees: 2
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

Recent news